Thetis Pharmaceuticals Announces U.S. Patent for Treatment of Colon Cancer
Expands Thetis composition of matter patent portfolio to treatment of solid tumor cancers.
ESSEX, CT – (March 12, 2024) – Thetis Pharmaceuticals LLC (“Thetis”), a pharmaceutical company developing an oral, small molecule Resolvin E1-based drug for treatment of chronic inflammatory diseases and solid tumor cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has granted US. Pat # 11,925,688 providing a method of use claim for TP-317 (Resolvin E1 magnesium di-lysinate) for treatment of colon cancer.
“TP-317 is a novel agonist of the LTB4-BLT1 pathway with unique therapeutic potential in cancer and chronic inflammatory diseases,” said Gary Mathias, co-founder and CEO of Thetis. “This patent provides method of use claim for treatment of colon cancer, which is the second leading cause of cancer death in the U.S.”
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Its lead candidate, TP-317, is a first-in-class oral RvE1 drug candidate that targets the LTB4-BLT1 pathway to harness the body’s natural ability to resolve disease and restore immune homeostasis. Thetis is backed by private investors, the National Institutes of Health (NIH), and prominent philanthropic organizations such as the Helmsley Charitable Trust, Crohn's & Colitis Foundation, and Kenneth Rainin Foundation.
Contact Information
Tracy Lessor
TLOW Communications, LLC
617-519-9827
tracy@tlowcommunications.com